Johnson & Johnson/Janssen COVID-19 Vaccine No Longer Authorized for Use, CR 118354
On June 1, 2023, the Food and Drug Administration (FDA) revoked the Emergency Use Authorization (EUA) for Johnson & Johnson/Janssen COVID-19 vaccine. As a result, the following codes are no longer authorized for use:
|
Code |
Description |
Effective Date |
End Date |
|
91303 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use |
02/27/2021 |
06/01/23 |
|
0031A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose |
02/27/2021 |
06/01/23 |
|
0034A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; booster dose |
10/20/21 |
06/01/23 |
Providers may visit the Maine CDC Immunization Program Website for up-to-date information on administering and ordering COVID-19 vaccines.
If you have questions about the use of any COVID-19 vaccines, please contact your Provider Relations Specialist.
Check out our new MaineCare logo! Learn more about this logo on the About Us page of our website.
